What is Vitrologic?
Since its inception in 1979, Vitrologic, previously known as Biochemed, has carved a niche in the collection and provision of human biologicals. The company's Specialty Sera donor operations are central to its business, facilitating the collection of bulk biologicals essential for manufacturing controls, calibrators, base matrices, and purified human proteins. Vitrologic distinguishes itself through complete vertical integration, encompassing its own donor center, laboratory, and manufacturing facilities. This comprehensive capability allows the company to offer source material, custom processing, testing, and data vital for research and development across diverse fields including allergy, infectious disease, coagulation, oncology, rheumatology, hematology, and gastroenterology. Their established network of physicians, group practices, and laboratories aids in locating study participants and donors, ensuring a robust supply chain for critical biological products.
How much funding has Vitrologic raised?
Vitrologic has raised a total of $56K across 1 funding round:
Debt
$56K
Debt (2021): $56K with participation from PPP
What's next for Vitrologic?
The substantial expansion capital infusion positions Vitrologic for significant growth and strategic development. As a company with deep roots in vertical integration and specialized biological collection, this latest round of financing is expected to fuel further scaling of operations, potentially enhancing its R&D capabilities or expanding its market reach within the allergy, infectious disease, and oncology sectors, among others. The company's ability to offer end-to-end solutions from donor collection to processed biological products provides a strong foundation for leveraging this investment to solidify its leadership in the human biologicals market.
See full Vitrologic company page
